Comparative pharmacology and toxicology of tramadol and tapentadol

被引:63
作者
Faria, J. [1 ,2 ,3 ,4 ]
Barbosa, J. [1 ,2 ,3 ,4 ]
Moreira, R. [1 ]
Queiros, O. [1 ]
Carvalho, F. [2 ]
Dinis-Oliveira, R. J. [1 ,2 ,3 ,4 ]
机构
[1] Univ Inst Hlth Sci IUCS, Inst Res & Adv Training Hlth Sci & Technol, IINFACTS, Dept Sci,CESPU,CRL, Gandra, Portugal
[2] Univ Porto, UCIBIO REQUIMTE, Fac Pharm, Lab Toxicol,Dept Biol Sci, Porto, Portugal
[3] Univ Porto, Fac Med, Dept Publ Hlth & Forens Sci, Porto, Portugal
[4] Univ Porto, Fac Med, Med Educ, Porto, Portugal
关键词
ATYPICAL OPIOID TAPENTADOL; PAIN MANAGEMENT; BLOOD-PRESSURE; RESPIRATORY DEPRESSION; N-DESMETHYLTAPENTADOL; LIQUID-CHROMATOGRAPHY; EXTENDED-RELEASE; RECEPTOR AGONIST; CEREBRAL-CORTEX; NONMEDICAL USE;
D O I
10.1002/ejp.1196
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Moderate-to-severe pain represents a heavy burden in patients' quality of life, and ultimately in the society and in healthcare costs. The aim of this review was to summarize data on tramadol and tapentadol adverse effects, toxicity, potential advantages and limitations according to the context of clinical use. We compared data on the pharmacological and toxicological profiles of tramadol and tapentadol, after an extensive literature search in the US National Library of Medicine (PubMed). Tramadol is a prodrug that acts through noradrenaline and serotonin reuptake inhibition, with a weak opioid component added by its metabolite O-desmethyltramadol. Tapentadol does not require metabolic activation and acts mainly through noradrenaline reuptake inhibition and has a strong opioid activity. Such features confer tapentadol potential advantages, namely lower serotonergic, dependence and abuse potential, more linear pharmacokinetics, greater gastrointestinal tolerability and applicability in the treatment of chronic and neuropathic pain. Although more studies are needed to provide clear guidance on the opioid of choice, tapentadol shows some advantages, as it does not require CYP450 system activation and has minimal serotonergic effects. In addition, it leads to less side effects and lower abuse liability. However, invivo and invitro studies have shown that tramadol and tapentadol cause similar toxicological damage. In this context, it is important to underline that the choice of opioid should be individually balanced and a tailored decision, based on previous experience and on the patient's profile, type of pain and context of treatment. SignificanceThis review underlines the need for a careful prescription of tramadol and tapentadol. Although both are widely prescribed synthetic opioid analgesics, their toxic effects and potential dependence are not completely understood yet. In particular, concerning tapentadol, further research is needed to better assess its toxic effects.
引用
收藏
页码:827 / 844
页数:18
相关论文
共 133 条
  • [11] Adolescent tramadol use and abuse in Egypt
    Bassiony, Medhat M.
    El-Deen, Ghada M. Salah
    Yousef, Usama
    Raya, Yasser
    Abdel-Ghani, Mohamed M.
    El-Gohari, Hayam
    Atwa, Samar A.
    [J]. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2015, 41 (03) : 206 - 211
  • [12] Beakley BD, 2015, PAIN PHYSICIAN, V18, P395
  • [13] A comparison of fentanyl with tramadol during propofol-based deep sedation for pediatric upper endoscopy
    Bedirli, Nurdan
    Egritas, Odul
    Cosarcan, Kaan
    Bozkirli, Fusun
    [J]. PEDIATRIC ANESTHESIA, 2012, 22 (02) : 150 - 155
  • [14] Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis
    Biondi, David M.
    Xiang, Jim
    Etropolski, Mila
    Moskovitz, Bruce
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (08) : 565 - 576
  • [15] Lost but making progress-Where will new analgesic drugs come from?
    Borsook, David
    Hargreaves, Richard
    Bountra, Chas
    Porreca, Frank
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (249)
  • [16] Opiate Analgesics as Negative Modulators of Adult Hippocampal Neurogenesis: Potential Implications in Clinical Practice
    Bortolotto, Valeria
    Grilli, Mariagrazia
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [17] Tapentadol Toxicity in Children
    Borys, Douglas
    Stanton, Matthew
    Gummin, David
    Drott, Tracy
    [J]. PEDIATRICS, 2015, 135 (02) : E392 - E396
  • [18] Determination of Tapentadol (Nucynta®) and N-Desmethyltapentadol in Authentic Urine Specimens by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
    Bourland, James A.
    Collins, Ayodele A.
    Chester, Scot A.
    Ramachandran, Sumankalai
    Backer, Ronald C.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2010, 34 (08) : 450 - 457
  • [19] The discovery and development of analgesics: new mechanisms, new modalities
    Burgess, Gillian
    Williams, Dic
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (11) : 3753 - 3759
  • [20] Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment
    Butler, Stephen F.
    McNaughton, Emily C.
    Black, Ryan A.
    [J]. PAIN MEDICINE, 2015, 16 (01) : 119 - 130